NR1H4 and biliary liver cirrhosis: In fact, the FXR agonist obeticholic acid (OCA; also known as 6-ethyl chenodeoxycholic acid (6-ECDCA) or INT-747) has been FDA approved for use in patients with primary biliary cholangitis (PBC)24,25.